{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T02:46:09Z","timestamp":1795056369443,"version":"4.10.2"},"reference-count":86,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T00:00:00Z","timestamp":1734307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T00:00:00Z","timestamp":1734307200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Antimicrob Resist"],"DOI":"10.1038\/s44259-024-00066-z","type":"journal-article","created":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T12:44:37Z","timestamp":1734353077000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Assessment of tuberculosis drug efficacy using preclinical animal models and in vitro predictive techniques"],"prefix":"10.1038","volume":"2","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6559-5936","authenticated-orcid":false,"given":"Hazem F. M.","family":"Abdelaal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan J.","family":"Berube","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brendan K.","family":"Podell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew H.","family":"Harband","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hadley E.","family":"Gary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Perez-Jaimes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David F.","family":"Ackart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie A.","family":"Reese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sasha E.","family":"Larsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiffany","family":"Pecor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David Z.","family":"Wilkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanya","family":"Parish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0114-0550","authenticated-orcid":false,"given":"Sara E.","family":"Maloney-Norcross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey B.","family":"Mecham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony J.","family":"Hickey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan L.","family":"Baldwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rhea N.","family":"Coler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,16]]},"reference":[{"key":"66_CR1","doi-asserted-by":"publisher","first-page":"e20","DOI":"10.1016\/S2666-5247(22)00359-7","volume":"4","author":"S Bagcchi","year":"2023","unstructured":"Bagcchi, S. WHO\u2019s Global Tuberculosis Report 2022. Lancet Microbe 4, e20 (2023).","journal-title":"Lancet Microbe"},{"key":"66_CR2","doi-asserted-by":"publisher","first-page":"230036","DOI":"10.1183\/20734735.0036-2023","volume":"19","author":"VA Adepoju","year":"2023","unstructured":"Adepoju, V. A. & Onyezue, O. I. Ending the TB pandemic: the urgency of a new and improved TB vaccine and the World Health Organization\u2019s TB Vaccine Accelerator Council. Breathe (Sheff) 19, 230036 (2023).","journal-title":"Breathe (Sheff)"},{"key":"66_CR3","doi-asserted-by":"publisher","first-page":"S193","DOI":"10.1016\/j.ijtb.2022.10.011","volume":"69","author":"HL Rieder","year":"2022","unstructured":"Rieder, H. L. Epidemiology of tuberculosis and respiratory diseases in the elderly: A global view. Indian J Tuberc 69, S193\u2013S195 (2022).","journal-title":"Indian J Tuberc"},{"key":"66_CR4","doi-asserted-by":"publisher","unstructured":"McQuaid, C. F. et al. The potential impact of COVID-19-related disruption on tuberculosis burden. Eur Respir J 56. https:\/\/doi.org\/10.1183\/13993003.01718-2020 (2020).","DOI":"10.1183\/13993003.01718-2020"},{"key":"66_CR5","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1183\/09031936.00188313","volume":"44","author":"C Lange","year":"2014","unstructured":"Lange, C. et al. Management of patients with multidrug-resistant\/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement. Eur Respir J 44, 23\u201363 (2014).","journal-title":"Eur Respir J"},{"key":"66_CR6","doi-asserted-by":"publisher","first-page":"a017863","DOI":"10.1101\/cshperspect.a017863","volume":"5","author":"KJ Seung","year":"2015","unstructured":"Seung, K. J., Keshavjee, S. & Rich, M. L. Multidrug-Resistant Tuberculosis and Extensively Drug-Resistant Tuberculosis. Cold Spring Harb Perspect Med. 5, a017863 (2015).","journal-title":"Cold Spring Harb Perspect Med."},{"key":"66_CR7","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1007\/s12098-022-04280-3","volume":"89","author":"T Singhal","year":"2022","unstructured":"Singhal, T. The New WHO Consolidated Guidelines for Management of Tuberculosis in Children and Adolescents: An Appraisal. Indian J Pediatr. 89, 743\u2013745 (2022).","journal-title":"Indian J Pediatr."},{"key":"66_CR8","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.mib.2011.08.003","volume":"14","author":"MA Fischbach","year":"2011","unstructured":"Fischbach, M. A. Combination therapies for combating antimicrobial resistance. Curr Opin Microbiol 14, 519\u2013523 (2011).","journal-title":"Curr Opin Microbiol"},{"key":"66_CR9","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1128\/AAC.49.6.2294-2301.2005","volume":"49","author":"AJ Lenaerts","year":"2005","unstructured":"Lenaerts, A. J. et al. Preclinical testing of the nitroimidazopyran PA-824 for activity against Mycobacterium tuberculosis in a series of in vitro and in vivo models. Antimicrob Agents Chemother 49, 2294\u20132301 (2005).","journal-title":"Antimicrob Agents Chemother"},{"key":"66_CR10","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1164\/rccm.200310-1380OC","volume":"169","author":"EL Nuermberger","year":"2004","unstructured":"Nuermberger, E. L. et al. Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis. Am J Respir Crit Care Med 169, 421\u2013426 (2004).","journal-title":"Am J Respir Crit Care Med"},{"key":"66_CR11","doi-asserted-by":"publisher","first-page":"4741","DOI":"10.1016\/j.bmcl.2013.07.006","volume":"23","author":"V Dartois","year":"2013","unstructured":"Dartois, V. & Barry, C. E. 3rd A medicinal chemists\u2019 guide to the unique difficulties of lead optimization for tuberculosis. Bioorg Med Chem Lett 23, 4741\u20134750 (2013).","journal-title":"Bioorg Med Chem Lett"},{"key":"66_CR12","doi-asserted-by":"publisher","unstructured":"Xu, J., et al. Comparative Efficacy of the Novel Diarylquinoline TBAJ-587 and Bedaquiline against a Resistant Rv0678 Mutant in a Mouse Model of Tuberculosis. Antimicrob Agents Chemother 65, https:\/\/doi.org\/10.1128\/AAC.02418-20 (2021).","DOI":"10.1128\/AAC.02418-20"},{"key":"66_CR13","doi-asserted-by":"publisher","unstructured":"Xu, J. et al. Contribution of Pretomanid to Novel Regimens Containing Bedaquiline with either Linezolid or Moxifloxacin and Pyrazinamide in Murine Models of Tuberculosis. Antimicrob Agents Chemother 63, https:\/\/doi.org\/10.1128\/AAC.00021-19 (2019).","DOI":"10.1128\/AAC.00021-19"},{"key":"66_CR14","doi-asserted-by":"publisher","unstructured":"Xu, J. et al. Verapamil Increases the Bioavailability and Efficacy of Bedaquiline but Not Clofazimine in a Murine Model of Tuberculosis. Antimicrob Agents Chemother 62, https:\/\/doi.org\/10.1128\/AAC.01692-17 (2018).","DOI":"10.1128\/AAC.01692-17"},{"key":"66_CR15","doi-asserted-by":"publisher","unstructured":"Xu, J. et al. Primary Clofazimine and Bedaquiline Resistance among Isolates from Patients with Multidrug-Resistant Tuberculosis. Antimicrob Agents Chemother 61, https:\/\/doi.org\/10.1128\/AAC.00239-17 (2017).","DOI":"10.1128\/AAC.00239-17"},{"key":"66_CR16","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1128\/AAC.01691-15","volume":"60","author":"R Tasneen","year":"2016","unstructured":"Tasneen, R. et al. Contribution of Oxazolidinones to the Efficacy of Novel Regimens Containing Bedaquiline and Pretomanid in a Mouse Model of Tuberculosis. Antimicrob Agents Chemother 60, 270\u2013277 (2016).","journal-title":"Antimicrob Agents Chemother"},{"key":"66_CR17","doi-asserted-by":"publisher","unstructured":"Pieterman, E. D. et al. Assessment of the Additional Value of Verapamil to a Moxifloxacin and Linezolid Combination Regimen in a Murine Tuberculosis Model. Antimicrob Agents Chemother 62, https:\/\/doi.org\/10.1128\/AAC.01354-18 (2018).","DOI":"10.1128\/AAC.01354-18"},{"key":"66_CR18","doi-asserted-by":"publisher","DOI":"10.1128\/aac.02310-21","volume":"66","author":"C Dide-Agossou","year":"2022","unstructured":"Dide-Agossou, C. et al. Combination of Mycobacterium tuberculosis RS Ratio and CFU Improves the Ability of Murine Efficacy Experiments to Distinguish between Drug Treatments. Antimicrob Agents Chemother 66, e0231021 (2022).","journal-title":"Antimicrob Agents Chemother"},{"key":"66_CR19","doi-asserted-by":"publisher","DOI":"10.1128\/aac.02398-21","volume":"66","author":"R Tasneen","year":"2022","unstructured":"Tasneen, R. et al. Novel Regimens of Bedaquiline-Pyrazinamide Combined with Moxifloxacin, Rifabutin, Delamanid and\/or OPC-167832 in Murine Tuberculosis Models. Antimicrob Agents Chemother 66, e0239821 (2022).","journal-title":"Antimicrob Agents Chemother"},{"key":"66_CR20","doi-asserted-by":"publisher","unstructured":"Li, S. Y., et al. Bactericidal and Sterilizing Activity of a Novel Regimen with Bedaquiline, Pretomanid, Moxifloxacin, and Pyrazinamide in a Murine Model of Tuberculosis. Antimicrob Agents Chemother. 61, https:\/\/doi.org\/10.1128\/AAC.00913-17 (2017).","DOI":"10.1128\/AAC.00913-17"},{"key":"66_CR21","doi-asserted-by":"publisher","first-page":"4496","DOI":"10.1128\/AAC.00506-13","volume":"57","author":"A Fillion","year":"2013","unstructured":"Fillion, A. et al. Impact of fluoroquinolone resistance on bactericidal and sterilizing activity of a moxifloxacin-containing regimen in murine tuberculosis. Antimicrob Agents Chemother. 57, 4496\u20134500 (2013).","journal-title":"Antimicrob Agents Chemother."},{"key":"66_CR22","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1128\/AAC.00074-08","volume":"52","author":"E Nuermberger","year":"2008","unstructured":"Nuermberger, E. et al. Powerful bactericidal and sterilizing activity of a regimen containing PA-824, moxifloxacin, and pyrazinamide in a murine model of tuberculosis. Antimicrob Agents Chemother 52, 1522\u20131524 (2008).","journal-title":"Antimicrob Agents Chemother"},{"key":"66_CR23","doi-asserted-by":"publisher","unstructured":"Furin, J. et al. Global Progress and Challenges in Implementing New Medications for Treating Multidrug-Resistant Tuberculosis. Emerg Infect Dis. 22, https:\/\/doi.org\/10.3201\/eid2203.151430 (2016).","DOI":"10.3201\/eid2203.151430"},{"key":"66_CR24","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1126\/science.339.6116.130","volume":"339","author":"J Cohen","year":"2013","unstructured":"Cohen, J. Infectious disease. Approval of novel TB drug celebrated-with restraint. Science 339, 130 (2013).","journal-title":"Science"},{"key":"66_CR25","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.tim.2013.05.002","volume":"21","author":"EB Wong","year":"2013","unstructured":"Wong, E. B., Cohen, K. A. & Bishai, W. R. Rising to the challenge: new therapies for tuberculosis. Trends Microbiol 21, 493\u2013501 (2013).","journal-title":"Trends Microbiol"},{"key":"66_CR26","doi-asserted-by":"publisher","first-page":"25273","DOI":"10.1074\/jbc.M803899200","volume":"283","author":"A Koul","year":"2008","unstructured":"Koul, A. et al. Diarylquinolines are bactericidal for dormant mycobacteria as a result of disturbed ATP homeostasis. J Biol Chem 283, 25273\u201325280 (2008).","journal-title":"J Biol Chem"},{"key":"66_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms4369","volume":"5","author":"A Koul","year":"2014","unstructured":"Koul, A. et al. Delayed bactericidal response of Mycobacterium tuberculosis to bedaquiline involves remodelling of bacterial metabolism. Nat Commun 5, 3369 (2014).","journal-title":"Nat Commun"},{"key":"66_CR28","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.1500106","volume":"1","author":"L Preiss","year":"2015","unstructured":"Preiss, L. et al. Structure of the mycobacterial ATP synthase Fo rotor ring in complex with the anti-TB drug bedaquiline. Sci Adv 1, e1500106 (2015).","journal-title":"Sci Adv"},{"key":"66_CR29","doi-asserted-by":"publisher","first-page":"e17556","DOI":"10.1371\/journal.pone.0017556","volume":"6","author":"N Veziris","year":"2011","unstructured":"Veziris, N., Ibrahim, M., Lounis, N., Andries, K. & Jarlier, V. Sterilizing activity of second-line regimens containing TMC207 in a murine model of tuberculosis. PLoS One 6, e17556 (2011).","journal-title":"PLoS One"},{"key":"66_CR30","doi-asserted-by":"publisher","first-page":"3114","DOI":"10.1128\/AAC.00384-12","volume":"56","author":"K Williams","year":"2012","unstructured":"Williams, K. et al. Sterilizing activities of novel combinations lacking first- and second-line drugs in a murine model of tuberculosis. Antimicrob Agents Chemother 56, 3114\u20133120 (2012).","journal-title":"Antimicrob Agents Chemother"},{"key":"66_CR31","doi-asserted-by":"publisher","first-page":"3271","DOI":"10.1128\/AAC.06126-11","volume":"56","author":"AH Diacon","year":"2012","unstructured":"Diacon, A. H. et al. Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistance. Antimicrob Agents Chemother 56, 3271\u20133276 (2012).","journal-title":"Antimicrob Agents Chemother"},{"key":"66_CR32","doi-asserted-by":"publisher","first-page":"2397","DOI":"10.1056\/NEJMoa0808427","volume":"360","author":"AH Diacon","year":"2009","unstructured":"Diacon, A. H. et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med 360, 2397\u20132405 (2009).","journal-title":"N Engl J Med"},{"key":"66_CR33","doi-asserted-by":"publisher","first-page":"5485","DOI":"10.1128\/AAC.05293-11","volume":"55","author":"R Tasneen","year":"2011","unstructured":"Tasneen, R. et al. Sterilizing activity of novel TMC207- and PA-824-containing regimens in a murine model of tuberculosis. Antimicrob Agents Chemother 55, 5485\u20135492 (2011).","journal-title":"Antimicrob Agents Chemother"},{"key":"66_CR34","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1164\/rccm.201410-1801OC","volume":"191","author":"AH Diacon","year":"2015","unstructured":"Diacon, A. H. et al. Bactericidal activity of pyrazinamide and clofazimine alone and in combinations with pretomanid and bedaquiline. Am J Respir Crit Care Med 191, 943\u2013953 (2015).","journal-title":"Am J Respir Crit Care Med"},{"key":"66_CR35","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1016\/S0140-6736(12)61080-0","volume":"380","author":"AH Diacon","year":"2012","unstructured":"Diacon, A. H. et al. 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial. Lancet 380, 986\u2013993 (2012).","journal-title":"Lancet"},{"key":"66_CR36","doi-asserted-by":"publisher","unstructured":"Berube, B. J. & Parish, T. Combinations of Respiratory Chain Inhibitors Have Enhanced Bactericidal Activity against Mycobacterium tuberculosis. Antimicrob Agents Chemother. 62, https:\/\/doi.org\/10.1128\/AAC.01677-17 (2018).","DOI":"10.1128\/AAC.01677-17"},{"key":"66_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.tube.2022.102272","volume":"137","author":"BJ Berube","year":"2022","unstructured":"Berube, B. J. et al. Characterizing in vivo loss of virulence of an HN878 Mycobacterium tuberculosis isolate from a genetic duplication event. Tuberculosis (Edinb) 137, 102272 (2022).","journal-title":"Tuberculosis (Edinb)"},{"key":"66_CR38","doi-asserted-by":"publisher","first-page":"e0214088","DOI":"10.1371\/journal.pone.0214088","volume":"14","author":"S Borrell","year":"2019","unstructured":"Borrell, S. et al. Reference set of Mycobacterium tuberculosis clinical strains: A tool for research and product development. PLoS One 14, e0214088 (2019).","journal-title":"PLoS One"},{"key":"66_CR39","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1099\/mic.0.033084-0","volume":"156","author":"M Gengenbacher","year":"2010","unstructured":"Gengenbacher, M., Rao, S. P. S., Pethe, K. & Dick, T. Nutrient-starved, non-replicating Mycobacterium tuberculosis requires respiration, ATP synthase and isocitrate lyase for maintenance of ATP homeostasis and viability. Microbiology (Reading) 156, 81\u201387 (2010).","journal-title":"Microbiology (Reading)"},{"key":"66_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.tube.2022.102302","volume":"138","author":"M Rais","year":"2023","unstructured":"Rais, M. et al. Immunogenicity and protection against Mycobacterium avium with a heterologous RNA prime and protein boost vaccine regimen. Tuberculosis (Edinb) 138, 102302 (2023).","journal-title":"Tuberculosis (Edinb)"},{"key":"66_CR41","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1021\/acsinfecdis.5b00127","volume":"2","author":"SM Irwin","year":"2016","unstructured":"Irwin, S. M. et al. Bedaquiline and Pyrazinamide Treatment Responses Are Affected by Pulmonary Lesion Heterogeneity in Mycobacterium tuberculosis Infected C3HeB\/FeJ Mice. ACS Infect Dis. 2, 251\u2013267 (2016).","journal-title":"ACS Infect Dis."},{"key":"66_CR42","first-page":"770","volume":"72","author":"GT Robertson","year":"2017","unstructured":"Robertson, G. T. et al. Spectinamides are effective partner agents for the treatment of tuberculosis in multiple mouse infection models. J Antimicrob Chemother. 72, 770\u2013777 (2017).","journal-title":"J Antimicrob Chemother."},{"key":"66_CR43","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.ijid.2016.08.027","volume":"52","author":"W Zhao","year":"2016","unstructured":"Zhao, W. et al. Interactions of linezolid and second-line anti-tuberculosis agents against multidrug-resistant Mycobacterium tuberculosis in vitro and in vivo. Int J Infect Dis. 52, 23\u201328 (2016).","journal-title":"Int J Infect Dis."},{"key":"66_CR44","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.1128\/AAC.37.11.2344","volume":"37","author":"SP Klemens","year":"1993","unstructured":"Klemens, S. P., DeStefano, M. S. & Cynamon, M. H. Therapy of multidrug-resistant tuberculosis: lessons from studies with mice. Antimicrob Agents Chemother. 37, 2344\u20132347 (1993).","journal-title":"Antimicrob Agents Chemother."},{"key":"66_CR45","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1128\/AAC.47.1.360-362.2003","volume":"47","author":"L Fattorini","year":"2003","unstructured":"Fattorini, L. et al. Activities of moxifloxacin alone and in combination with other antimicrobial agents against multidrug-resistant Mycobacterium tuberculosis infection in BALB\/c mice. Antimicrob Agents Chemother. 47, 360\u2013362 (2003).","journal-title":"Antimicrob Agents Chemother."},{"key":"66_CR46","doi-asserted-by":"publisher","first-page":"e344","DOI":"10.1371\/journal.pmed.0040344","volume":"4","author":"IM Rosenthal","year":"2007","unstructured":"Rosenthal, I. M. et al. Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model. PLoS Med 4, e344 (2007).","journal-title":"PLoS Med"},{"key":"66_CR47","doi-asserted-by":"publisher","unstructured":"Maloney, S. E. et al. Preparation Strategies of the Anti-Mycobacterial Drug Bedaquiline for Intrapulmonary Routes of Administration. Pharmaceuticals (Basel) 16, https:\/\/doi.org\/10.3390\/ph16050729 (2023).","DOI":"10.3390\/ph16050729"},{"key":"66_CR48","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1089\/adt.2015.672","volume":"14","author":"P Chase","year":"2016","unstructured":"Chase, P. et al. An Automated Miniaturized Method to Perform and Analyze Antimicrobial Drug Synergy Assays. Assay Drug Dev Technol 14, 58\u201366 (2016).","journal-title":"Assay Drug Dev Technol"},{"key":"66_CR49","doi-asserted-by":"publisher","unstructured":"Nikolic, I., et al. An Optimized Checkerboard Method for Phage-Antibiotic Synergy Detection. Viruses 14, https:\/\/doi.org\/10.3390\/v14071542 (2022).","DOI":"10.3390\/v14071542"},{"key":"66_CR50","doi-asserted-by":"publisher","unstructured":"Brennan-Krohn, T. & Kirby, J. E. Antimicrobial Synergy Testing by the Inkjet Printer-assisted Automated Checkerboard Array and the Manual Time-kill Method. J Vis Exp. https:\/\/doi.org\/10.3791\/58636 (2019).","DOI":"10.3791\/58636"},{"key":"66_CR51","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1093\/clinids\/4.2.276","volume":"4","author":"CW Norden","year":"1982","unstructured":"Norden, C. W. Problems in determination of antibiotic synergism in vitro. Rev Infect Dis. 4, 276\u2013281 (1982).","journal-title":"Rev Infect Dis."},{"key":"66_CR52","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1128\/AAC.00978-10","volume":"55","author":"S Shang","year":"2011","unstructured":"Shang, S. et al. Activities of TMC207, rifampin, and pyrazinamide against Mycobacterium tuberculosis infection in guinea pigs. Antimicrob Agents Chemother. 55, 124\u2013131 (2011).","journal-title":"Antimicrob Agents Chemother."},{"key":"66_CR53","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.tube.2007.12.003","volume":"88","author":"GS Palanisamy","year":"2008","unstructured":"Palanisamy, G. S. et al. Disseminated disease severity as a measure of virulence of Mycobacterium tuberculosis in the guinea pig model. Tuberculosis (Edinb) 88, 295\u2013306 (2008).","journal-title":"Tuberculosis (Edinb)"},{"key":"66_CR54","doi-asserted-by":"publisher","unstructured":"Mirzayev, F. et al. World Health Organization recommendations on the treatment of drug-resistant tuberculosis, 2020 update. Eur Respir J. 57, https:\/\/doi.org\/10.1183\/13993003.03300-2020 (2021).","DOI":"10.1183\/13993003.03300-2020"},{"key":"66_CR55","doi-asserted-by":"publisher","first-page":"S12","DOI":"10.1016\/j.ijid.2023.03.013","volume":"130","author":"E Vanino","year":"2023","unstructured":"Vanino, E. et al. Update of drug-resistant tuberculosis treatment guidelines: A turning point. Int J Infect Dis. 130, S12\u2013S15 (2023).","journal-title":"Int J Infect Dis."},{"key":"66_CR56","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-48410-y","volume":"9","author":"K Yilancioglu","year":"2019","unstructured":"Yilancioglu, K. & Cokol, M. Design of high-order antibiotic combinations against M. tuberculosis by ranking and exclusion. Sci Rep 9, 11876 (2019).","journal-title":"Sci Rep"},{"key":"66_CR57","doi-asserted-by":"publisher","unstructured":"Ma, S. et al. Transcriptomic Signatures Predict Regulators of Drug Synergy and Clinical Regimen Efficacy against Tuberculosis. mBio. 10, https:\/\/doi.org\/10.1128\/mBio.02627-19 (2019).","DOI":"10.1128\/mBio.02627-19"},{"key":"66_CR58","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.3389\/fmicb.2017.02075","volume":"8","author":"YS Patel","year":"2017","unstructured":"Patel, Y. S. & Mehra, S. Synergistic Response of Rifampicin with Hydroperoxides on Mycobacterium: A Mechanistic Study. Front Microbiol 8, 2075 (2017).","journal-title":"Front Microbiol"},{"key":"66_CR59","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.ejmech.2018.05.049","volume":"155","author":"TM Dhameliya","year":"2018","unstructured":"Dhameliya, T. M. et al. Benzo[d]thiazole-2-carbanilides as new anti-TB chemotypes: Design, synthesis, biological evaluation, and structure-activity relationship. Eur J Med. Chem. 155, 364\u2013380 (2018).","journal-title":"Eur J Med. Chem."},{"key":"66_CR60","doi-asserted-by":"publisher","unstructured":"Genestet, C. et al. Assessing the Combined Antibacterial Effect of Isoniazid and Rifampin on Four Mycobacterium tuberculosis Strains Using In Vitro Experiments and Response-Surface Modeling. Antimicrob Agents Chemother 62, https:\/\/doi.org\/10.1128\/AAC.01413-17 (2018).","DOI":"10.1128\/AAC.01413-17"},{"key":"66_CR61","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1111\/lam.12195","volume":"58","author":"N Guo","year":"2014","unstructured":"Guo, N. et al. In vitro activity of isoimperatorin, alone and in combination, against Mycobacterium tuberculosis. Lett Appl Microbiol 58, 344\u2013349 (2014).","journal-title":"Lett Appl Microbiol"},{"key":"66_CR62","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.ijantimicag.2015.10.016","volume":"47","author":"A Lopez-Gavin","year":"2016","unstructured":"Lopez-Gavin, A. et al. In vitro time-kill curves study of three antituberculous combinations against Mycobacterium tuberculosis clinical isolates. Int J Antimicrob Agents 47, 97\u2013100 (2016).","journal-title":"Int J Antimicrob Agents"},{"key":"66_CR63","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/j.ijantimicag.2015.08.004","volume":"46","author":"A Lopez-Gavin","year":"2015","unstructured":"Lopez-Gavin, A., Tudo, G., Vergara, A., Hurtado, J. C. & Gonzalez-Martin, J. In vitro activity against Mycobacterium tuberculosis of levofloxacin, moxifloxacin and UB-8902 in combination with clofazimine and pretomanid. Int J Antimicrob Agents 46, 582\u2013585 (2015).","journal-title":"Int J Antimicrob Agents"},{"key":"66_CR64","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1002\/iub.1526","volume":"68","author":"AH Ngwane","year":"2016","unstructured":"Ngwane, A. H. et al. Design, synthesis, and In vitro antituberculosis activity of 2(5H)-Furanone derivatives. IUBMB Life 68, 612\u2013620 (2016).","journal-title":"IUBMB Life"},{"key":"66_CR65","doi-asserted-by":"publisher","unstructured":"Pandey, R., et al. Dual beta-Lactam Combinations Highly Active against Mycobacterium abscessus Complex In Vitro. mBio. 10, https:\/\/doi.org\/10.1128\/mBio.02895-18 (2019).","DOI":"10.1128\/mBio.02895-18"},{"key":"66_CR66","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.ijantimicag.2012.11.011","volume":"41","author":"E Rey-Jurado","year":"2013","unstructured":"Rey-Jurado, E., Tudo, G., de la Bellacasa, J. P., Espasa, M. & Gonzalez-Martin, J. In vitro effect of three-drug combinations of antituberculous agents against multidrug-resistant Mycobacterium tuberculosis isolates. Int J Antimicrob Agents 41, 278\u2013280 (2013).","journal-title":"Int J Antimicrob Agents"},{"key":"66_CR67","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.tube.2012.01.005","volume":"92","author":"E Rey-Jurado","year":"2012","unstructured":"Rey-Jurado, E., Tudo, G., Martinez, J. A. & Gonzalez-Martin, J. Synergistic effect of two combinations of antituberculous drugs against Mycobacterium tuberculosis. Tuberculosis (Edinb) 92, 260\u2013263 (2012).","journal-title":"Tuberculosis (Edinb)"},{"key":"66_CR68","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.tube.2018.05.005","volume":"111","author":"NCS Santos","year":"2018","unstructured":"Santos, N. C. S. et al. Combinatory activity of linezolid and levofloxacin with antituberculosis drugs in Mycobacterium tuberculosis. Tuberculosis (Edinb) 111, 41\u201344 (2018).","journal-title":"Tuberculosis (Edinb)"},{"key":"66_CR69","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1128\/AAC.01035-15","volume":"60","author":"D Zhang","year":"2016","unstructured":"Zhang, D., Wang, Y., Lu, J. & Pang, Y. In Vitro Activity of beta-Lactams in Combination with beta-Lactamase Inhibitors against Multidrug-Resistant Mycobacterium tuberculosis Isolates. Antimicrob Agents Chemother 60, 393\u2013399 (2016).","journal-title":"Antimicrob Agents Chemother"},{"key":"66_CR70","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ijantimicag.2014.10.002","volume":"45","author":"W Ni","year":"2015","unstructured":"Ni, W. et al. In vitro synergy of polymyxins with other antibiotics for Acinetobacter baumannii: a systematic review and meta-analysis. Int J Antimicrob Agents 45, 8\u201318 (2015).","journal-title":"Int J Antimicrob Agents"},{"key":"66_CR71","unstructured":"Cole, S. T. et al. Deciphering the biology of mycobacterium tuberculosis from the complete genome sequence. Nature., (1998)."},{"key":"66_CR72","doi-asserted-by":"crossref","unstructured":"Gagneux, S. (2018). Ecology and evolution of Mycobacterium tuberculosis. Nature Reviews Microbiology. Nature Publishing Group.","DOI":"10.1038\/nrmicro.2018.8"},{"key":"66_CR73","doi-asserted-by":"publisher","first-page":"2605","DOI":"10.1093\/jac\/dkz215","volume":"74","author":"R Jajou","year":"2019","unstructured":"Jajou, R. et al. WGS more accurately predicts susceptibility of Mycobacterium tuberculosis to first-line drugs than phenotypic testing. J Antimicrob Chemother. 74, 2605\u20132616 (2019).","journal-title":"J Antimicrob Chemother."},{"key":"66_CR74","doi-asserted-by":"publisher","unstructured":"Yu, X. et al. In Vitro Activities of Bedaquiline and Delamanid against Nontuberculous Mycobacteria Isolated in Beijing, China. Antimicrob Agents Chemother 63, https:\/\/doi.org\/10.1128\/AAC.00031-19 (2019).","DOI":"10.1128\/AAC.00031-19"},{"key":"66_CR75","doi-asserted-by":"publisher","first-page":"3302","DOI":"10.1016\/j.xphs.2019.05.024","volume":"108","author":"RA Pitner","year":"2019","unstructured":"Pitner, R. A. et al. A Spray-Dried Combination of Capreomycin and CPZEN-45 for Inhaled Tuberculosis Therapy. J Pharm Sci 108, 3302\u20133311 (2019).","journal-title":"J Pharm Sci"},{"key":"66_CR76","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01412-21","volume":"65","author":"D Almeida","year":"2021","unstructured":"Almeida, D. et al. Comparative Efficacy of the Novel Diarylquinoline TBAJ-876 and Bedaquiline against a Resistant Rv0678 Mutant in a Mouse Model of Tuberculosis. Antimicrob Agents Chemother 65, e0141221 (2021).","journal-title":"Antimicrob Agents Chemother"},{"key":"66_CR77","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.ebiom.2018.01.005","volume":"28","author":"NA Ismail","year":"2018","unstructured":"Ismail, N. A. et al. Defining Bedaquiline Susceptibility, Resistance, Cross-Resistance and Associated Genetic Determinants: A Retrospective Cohort Study. EBioMedicine 28, 136\u2013142 (2018).","journal-title":"EBioMedicine"},{"key":"66_CR78","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.diagmicrobio.2019.02.012","volume":"94","author":"Y Pang","year":"2019","unstructured":"Pang, Y. et al. No in vitro synergistic effect of bedaquiline combined with fluoroquinolones, linezolid, and clofazimine against extensively drug-resistant tuberculosis. Diagn Microbiol Infect Dis. 94, 361\u2013364 (2019).","journal-title":"Diagn Microbiol Infect Dis."},{"key":"66_CR79","doi-asserted-by":"publisher","first-page":"104994","DOI":"10.1016\/j.meegid.2021.104994","volume":"93","author":"A Ordaz-Vazquez","year":"2021","unstructured":"Ordaz-Vazquez, A. et al. Genetic diversity and primary drug resistance transmission in Mycobacterium tuberculosis in southern Mexico. Infect Genet Evol. 93, 104994 (2021).","journal-title":"Infect Genet Evol."},{"key":"66_CR80","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/s12866-021-02174-6","volume":"21","author":"AV Singh","year":"2021","unstructured":"Singh, A. V. et al. Genetic variability in multidrug-resistant Mycobacterium tuberculosis isolates from patients with pulmonary tuberculosis in North India. BMC Microbiol. 21, 123 (2021).","journal-title":"BMC Microbiol."},{"key":"66_CR81","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1007\/978-1-0716-1460-0_30","volume":"2314","author":"N Van","year":"2021","unstructured":"Van, N., Degefu, Y. N. & Aldridge, B. B. Efficient Measurement of Drug Interactions with DiaMOND (Diagonal Measurement of N-Way Drug Interactions). Methods Mol Biol. 2314, 703\u2013713 (2021).","journal-title":"Methods Mol Biol."},{"key":"66_CR82","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1016\/j.ajpath.2013.12.015","volume":"184","author":"BK Podell","year":"2014","unstructured":"Podell, B. K. et al. Increased severity of tuberculosis in Guinea pigs with type 2 diabetes: a model of diabetes-tuberculosis comorbidity. Am J Pathol. 184, 1104\u20131118 (2014).","journal-title":"Am J Pathol."},{"key":"66_CR83","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-73212-y","volume":"10","author":"JDH Frenkel","year":"2020","unstructured":"Frenkel, J. D. H. et al. Metformin enhances protection in guinea pigs chronically infected with Mycobacterium tuberculosis. Sci Rep 10, 16257 (2020).","journal-title":"Sci Rep"},{"key":"66_CR84","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s00281-015-0537-x","volume":"38","author":"D Kiran","year":"2016","unstructured":"Kiran, D., Podell, B. K., Chambers, M. & Basaraba, R. J. Host-directed therapy targeting the Mycobacterium tuberculosis granuloma: a review. Semin Immunopathol. 38, 167\u2013183 (2016).","journal-title":"Semin Immunopathol."},{"key":"66_CR85","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1128\/AAC.03822-14","volume":"59","author":"R Tasneen","year":"2015","unstructured":"Tasneen, R. et al. Contribution of the nitroimidazoles PA-824 and TBA-354 to the activity of novel regimens in murine models of tuberculosis. Antimicrob Agents Chemother. 59, 129\u2013135 (2015).","journal-title":"Antimicrob Agents Chemother."},{"key":"66_CR86","doi-asserted-by":"publisher","first-page":"e0217670","DOI":"10.1371\/journal.pone.0217670","volume":"14","author":"PO Staff","year":"2019","unstructured":"Staff, P. O. Correction: Artificial intelligence enabled parabolic response surface platform identifies ultra-rapid near-universal TB drug treatment regimens comprising approved drugs. PLoS One 14, e0217670 (2019).","journal-title":"PLoS One"}],"container-title":["npj Antimicrobials and Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s44259-024-00066-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s44259-024-00066-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s44259-024-00066-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T14:10:27Z","timestamp":1734358227000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s44259-024-00066-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,16]]},"references-count":86,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["66"],"URL":"https:\/\/doi.org\/10.1038\/s44259-024-00066-z","relation":{},"ISSN":["2731-8745"],"issn-type":[{"value":"2731-8745","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,16]]},"assertion":[{"value":"2 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"49"}}